AU2003228339A1 - Prevention and treatment of disease using angiogenesis-and/or tumor antigens - Google Patents

Prevention and treatment of disease using angiogenesis-and/or tumor antigens

Info

Publication number
AU2003228339A1
AU2003228339A1 AU2003228339A AU2003228339A AU2003228339A1 AU 2003228339 A1 AU2003228339 A1 AU 2003228339A1 AU 2003228339 A AU2003228339 A AU 2003228339A AU 2003228339 A AU2003228339 A AU 2003228339A AU 2003228339 A1 AU2003228339 A1 AU 2003228339A1
Authority
AU
Australia
Prior art keywords
angiogenesis
disease
prevention
treatment
tumor antigens
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003228339A
Other versions
AU2003228339A8 (en
Inventor
Neil Berinstein
Corey Lovitt
Mark Parrington
Artur Pedyczak
Laszlo Radvanyi
Devender Singh-Sandhu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Pasteur Inc
Original Assignee
Aventis Pasteur Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pasteur Inc filed Critical Aventis Pasteur Inc
Publication of AU2003228339A1 publication Critical patent/AU2003228339A1/en
Publication of AU2003228339A8 publication Critical patent/AU2003228339A8/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/515—Angiogenesic factors; Angiogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/023—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a poxvirus
AU2003228339A 2002-03-20 2003-03-20 Prevention and treatment of disease using angiogenesis-and/or tumor antigens Abandoned AU2003228339A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US36598202P 2002-03-20 2002-03-20
US60/365,982 2002-03-20
PCT/US2003/008536 WO2003080800A2 (en) 2002-03-20 2003-03-20 Prevention and treatment of disease using angiogenesis-and/or tumor antigens

Publications (2)

Publication Number Publication Date
AU2003228339A1 true AU2003228339A1 (en) 2003-10-08
AU2003228339A8 AU2003228339A8 (en) 2003-10-08

Family

ID=28454736

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003228339A Abandoned AU2003228339A1 (en) 2002-03-20 2003-03-20 Prevention and treatment of disease using angiogenesis-and/or tumor antigens

Country Status (2)

Country Link
AU (1) AU2003228339A1 (en)
WO (1) WO2003080800A2 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2408328C (en) 2000-05-10 2012-04-17 Aventis Pasteur Limited Immunogenic polypeptides encoded by mage minigenes and uses thereof
AU2003223527B2 (en) 2002-04-09 2009-01-15 Sanofi Pasteur Limited Modified CEA nucleic acid and expression vectors
BRPI0413334A (en) * 2003-09-05 2006-10-10 Sanofi Pasteur Ltd multigene vectors for melanoma
KR101162970B1 (en) 2003-10-08 2012-07-12 테리온 바이오로직스, 인크. Modified CEA/B7 vector
WO2005068640A2 (en) * 2003-12-23 2005-07-28 Aventis Pasteur, Inc. Modified ksa and uses thereof
US20100028256A1 (en) 2006-11-09 2010-02-04 St Croix Brad Differential gene expression in physiological and pathological angiogenesis
WO2008101118A2 (en) 2007-02-14 2008-08-21 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services A gene expression signature identifying pro-angiogenic genes in ovarian tumor endothelial cell isolates

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030073613A1 (en) * 2000-03-22 2003-04-17 Mary Gerritsen Angiogenisis associated proteins, and nucleic acids encoding the same

Also Published As

Publication number Publication date
WO2003080800A2 (en) 2003-10-02
WO2003080800A3 (en) 2004-01-15
AU2003228339A8 (en) 2003-10-08

Similar Documents

Publication Publication Date Title
AU2003290548A1 (en) Prevention and treatment of synucleinopathic disease
WO2004030615A8 (en) Compositions and methods for the diagnosis and treatment of tumor
WO2004016225A8 (en) Compositions and methods for the diagnosis and treatment of tumor
EP1571968A3 (en) Compositions and methods for the diagnosis and treatment of tumor
WO2004045516A9 (en) Compositions and methods for the diagnosis and treatment of tumor
WO2003072035A8 (en) Compositions and methods for the treatment of immune related diseases
WO2004041170A9 (en) Compositions and methods for the treatment of immune related diseases
AU2002323258A1 (en) Diagnosis and treatment of vascular disease
WO2004024097A9 (en) Compositions and methods for the treatment of immune related diseases
EP1572091A3 (en) Compositions and methods for the diagnosis and treatment of tumor
WO2004060270A8 (en) Compositions and methods for the diagnosis and treatment of tumor
AU2002367535A1 (en) Diagnosis and treatment of vascular disease
PL372928A1 (en) Use of osteoprotegerin for the treatment and/or prevention of fibrotic disease
WO2003057160A8 (en) Compositions and methods for the diagnosis and treatment of tumor
AU2002239491A1 (en) Methods for the treatment of cancer and other diseases and methods of developing the same
WO2004104039A8 (en) Tumor antigens for prevention and/or treatment of cancer
AU2002326813A1 (en) Diagnosis and treatment of vascular disease
AU2002313426A1 (en) Tumor antigens for prevention and/or treatment of cancer
AU2003228339A1 (en) Prevention and treatment of disease using angiogenesis-and/or tumor antigens
AU2002341880A1 (en) Diagnosis and treatment of vascular disease
AU2002341604A1 (en) Diagnosis and treatment of vascular disease
AU2002330724A1 (en) Diagnosis, prevention and treatment of cancer
AU2003213898A1 (en) Prevention and treatment of mycoplasma-associated diseases
AU2003245858A1 (en) Uses of ngal-binding substances in the diagnosis and treatment of cancer diseases
EP1409734A4 (en) Diagnosis and treatment of cancer

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase